Heather Wakelee, MD
Enriched profileProfessor of Medicine and Chief of the Division of Oncology, Stanford University · Stanford University
Heather Wakelee is Professor of Medicine and Chief of the Division of Oncology, Stanford University at Stanford University. OpenAlex indexes 1,023 publications with 35,018 citations (h-index 89); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 23 Oct 2026
Heather Wakelee, MD, is Professor of Medicine and Chief of the Division of Oncology, Stanford University. The public record shows 1,023 publications with 35,018 citations (h-index 89), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 13 companies, 3 NIH-funded awards (2008–2018).
- Most recent indexed publication: 2026 · Nature reviews. Clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 314.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Sponsor: Xcovery Holdings, Inc.
Industry payments
Updated 23 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Chugai Pharmaceutical Co., Ltd.Program year20253 payments$15,674openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20253 payments
- AstraZeneca UK LimitedProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
3 NIH research awards on record, funded 2008–2018 per NIH RePORTER. The latest:
Congress activity
Updated 23 Oct 2026
167 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Outcomes of atypical EGFR mutations in early-stage EGFR -mutated non-small cell lung cancer (NSCLC).
ASCO Annual Meeting
ASCO2026Co-author - IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
ASCO Annual Meeting
ASCO2025Presenting author - Oncoshare-Lung: Novel three-way linkage of neighboring academic and community medical centers to state cancer registry for lung cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.
Nature reviews. Clinical oncology
Review2026 - Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.
British journal of cancer
Article2026 - Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.
Cancer discovery
Article2026 - A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.
European journal of cardio-thoracic surgery
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageArticle2,216 citations2014
- 02
- 03
- 04Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerArticle1,158 citations2023
- 05Integrated digital error suppression for improved detection of circulating tumor DNAArticle1,103 citations2016
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
profiles.stanford.edu/heather-wakelee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Doximity
doximity.com/pub/heather-wakelee-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
med.stanford.edu/cancer/about/news/wakelee-honored-with-2026-giants-of-cancer-care-award.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.stanford.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗
- Undergraduate degree
Princeton University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗
- Fellow
American Society of Clinical Oncology (FASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Member
ECOG-ACRIN Executive Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.stanford.edu ↗ - Associate Editor-in-Chief
Translational Lung Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗ - Deputy Director
Stanford Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.stanford.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →blog.ecog-acrin.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Parsonnet, MD
Stanford University
Pamela Munster, MD
Stanford University
Martha Morrell, MD
Stanford University
Alexander Sandhu, MD
Stanford University
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center